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Abstract: Evidence shows that weight loss improves insulin sensitivity but few studies have examined
the effect of macronutrient composition independently of weight loss on direct measures of insulin
sensitivity. We randomised 89 overweight or obese women to either a standard diet (StdD), that
was intended to be low in fat and relatively high in carbohydrate (n = 42) or to a relatively high
protein (up to 30% of energy), relatively high fibre (>30 g/day) diet (HPHFib) (n = 47) for 10 weeks.
Advice regarding strict adherence to energy intake goals was not given. Insulin sensitivity and
secretion was assessed by a novel method—the Dynamic Insulin Sensitivity and Secretion Test (DISST).
Although there were significant improvements in body composition and most cardiometabolic risk
factors on HPHFib, insulin sensitivity was reduced by 19.3% (95% CI: 31.8%, 4.5%; p = 0.013) in
comparison with StdD. We conclude that the reduction in insulin sensitivity after a diet relatively
high in both protein and fibre, despite cardiometabolic improvements, suggests insulin sensitivity
may reflect metabolic adaptations to dietary composition for maintenance of glucose homeostasis,
rather than impaired metabolism.
Keywords: diet; dietary protein; dietary fibre; insulin sensitivity assessment; insulin sensitivity;
insulin resistance; metabolic syndrome
1. Introduction
There is considerable evidence to show that weight loss can improve insulin sensitivity and
reduce the risk of diabetes and cardiovascular disease (CVD) [1,2]. Few studies, however, have
examined the effect of diet intervention on direct measures of insulin sensitivity (IS), particularly in
the context of weight maintenance. However, there is a substantial body of literature to show that
variations in the macronutrient composition of diets can modify the cardiometabolic abnormalities
associated with insulin resistance (IR) and therefore reduce the risk of diabetes. Low fat, high
carbohydrate diets have been shown to raise triglyceride (TG) levels and to reduce high density
lipoprotein (HDL) concentrations [3] whereas carbohydrate restriction may have the opposite effect,
while also having a positive influence of promoting low density lipoprotein (LDL) particle size [4].
High protein diets have become a popular approach to weight loss and improving body composition,
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with increasing evidence showing modest benefits over standard protein, relatively high carbohydrate
diets, at least in the relatively short term (one to two years) [5]. An alternative approach to reducing
the metabolic abnormalities associated with low fat, high carbohydrate diets is to modify the quality
of the carbohydrate consumed. There is some experimental and much epidemiological evidence to
suggest that high fibre (particularly soluble fibre), low glycemic index (GI) carbohydrates, derived
from minimally processed wholegrain cereals, fruit, vegetables and legumes may improve insulin
sensitivity, maintain glucose homeostasis, reduce postprandial insulin concentrations, and reduce
blood pressure in comparison with refined and high GI carbohydrates [6].
The gold-standard method for assessing insulin sensitivity is the hyperinsulinemic euglycaemic
clamp [7]. However the clamp is rarely used, as it is technically difficult and time-consuming, and
because highly trained clinicians are required to perform the test, it is expensive to conduct [8].
Numerous techniques have been developed to simplify the measurement of IS but this has been
at the expense of reliability and reproducibility [7]. Therefore, researchers have more frequently
used surrogate indices of IS, based on fasting blood parameters, such as the homeostatic model of
assessment (HOMA) [9] and the McAuley [10] methods. Such methods have been developed to
describe the relationship of IS to disease progression in longitudinal population studies, but relatively
poor reproducibility and reliability limits their usefulness for detecting dietary-induced changes in
IS, in clinical studies [8]. The Dynamic Insulin Sensitivity and Secretion Test (DISST) was developed
to address these issues [11]. The DISST is a variation of the infrequently sampled, low dose
insulin-modified intravenous glucose tolerance test (IM-IVGTT) that can simultaneously provide
highly reproducible estimates of IS and beta cell function [11].
The aim of this study was to examine the effect of a reduced carbohydrate diet that was moderately
high in both protein and dietary fiber (HPHFib diet) on IS and insulin secretion, using the DISST
method, in overweight and obese women at risk of diabetes, independently of weight loss.
2. Materials and Methods
2.1. Subjects and Experimental Protocol
The subjects, study design and diets have been previously described [12]. In brief, 89 women at
risk of diabetes, who met screening criteria, were randomly assigned to either a standard diet (StdD)
or a relatively high protein and high fibre diet (HPHFib) for 10 weeks. Women on medications to treat
metabolic syndrome risk factors (raised blood pressure, raised lipids or abnormal glucose control) were
not excluded as the aim was to recruit a cohort who were likely to be insulin resistant and at high risk
of diabetes. Advice regarding strict adherence to energy intake goals was not given (i.e., total energy
intakes were ad libitum). Eighty-nine women were randomly assigned to treatment, 6 withdrew before
receiving the allocated treatment, 8 withdrew during the treatment period and 75 women completed
the entire study.
At baseline, week 4 and week 10, measurements of height, weight, waist circumference and
seated blood pressure were taken and fasting blood samples were collected for the measurement of
serum lipids, and plasma glucose and insulin (in vacutainers containing antiglycolytic and/or EDTA
anticoagulants). A DISST test was then carried out. Body composition was measured by dual x-ray
absorptiometry (DXA) at baseline and week 10 only.
Each subject gave informed, written consent and all experimental procedures were approved by
the University of Otago Human Ethics Committee (reference 06/182). The trial was registered with the
Australian New Zealand Clinical Trials Registry (ACTRN12607000154404).
2.2. Diets
The standard diet (StdD) group received dietary advice based on the New Zealand Food and
Nutrition Guidelines for Healthy Adults [13]. Dietary goals were for approximately 20% of total
energy (TE) to be derived from protein, 50% from carbohydrate and 30% from total fat with <10%
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from saturated fat. Dietary fibre intake was to be ≥25 g/day. The StdD group were given a resource
available from the Ministry of Health in New Zealand, designed to facilitate adherence to these
guidelines, and a food group checklist which provided daily serving targets for major food groups.
Tailored dietary advice based on these recommendations was delivered by the researcher (LTM) during
individual 45–60 min counselling sessions at week 0 and week 5. Participants were encouraged to
make fortnightly appointments to monitor progress and discuss strategies for maintaining adherence
to the diet, but this was not compulsory.
The HPHFib diet was designed to achieve 30% TE from protein, 50% from carbohydrate, 20%
from fat, and a dietary fibre intake of ≥35 g/day. Individuals were asked to increase their usual
protein intake with lean meats, fish or low-fat dairy foods and to choose carbohydrates that were
particularly high in soluble fibre, such as oats, certain legumes, nuts, dried fruit and stone fruits as well
as wholegrain breads and cereals. Restriction of fat intake was necessary, in order to achieve the dietary
fibre and protein goals, without increasing energy intakes or requiring a dietary fibre supplement.
Consumption of refined carbohydrates including white bread, white rice, pasta, cakes, biscuits and
scones was discouraged. The HPHFib group was given material especially prepared for this study,
including recipes and sample diet plans, since relevant material was not readily available. Because the
HPHFib diet would not have been familiar to the typical New Zealander, participants were optionally
provided with a variety of pre-prepared frozen main course meals, especially formulated to be high in
protein and fibre as well as 30 g/day high protein whey concentrate powder (NZMP™ Whey Protein
Concentrate 392, Fonterra Co-operative Group Limited, New Zealand), wholegrain breakfast cereal
and bread, canned beans and canned fish. The high protein whey powder was supplied to enable
participants to maintain a relatively conventional eating plan, based around a cereal-based breakfast,
while also increasing protein intake. Tailored dietary advice based on these recommendations was
delivered by the researcher (LTM) during individual 45–60 min counselling sessions at week 0 and
week 5. Participants met with the researcher on a weekly basis in subsequent weeks to monitor
progress and discuss strategies for maintaining adherence to the diet. Thus, the HPHFib group was
provided with a more intensive treatment than the StdD group.
For both groups, during the initial 4-week study phase, advice was given regarding food choices
necessary to achieve the required macronutrient composition while maintaining usual weight. This was
to allow us to examine whether dietary composition influences insulin sensitivity independently of
weight loss. During the following 6 weeks, they were encouraged to continue the recommended
dietary pattern, but were not required to maintain their baseline weight; that is, they could reduce their
food intake if they had a reduced appetite as a result of their dietary changes. This was a pragmatic
decision in recognition that overweight women volunteering for dietary intervention studies will be
motivated to reduce their weight and that it could be challenging to maintain energy intake on the
HPHFib diet because of the increased volume of food.
Participants completed a weighed 3-day diet record, including 2 non-consecutive weekdays and
one weekend day, prior to commencing the intervention and at week 8. Dietary intakes of various
nutrients were calculated using the Diet Cruncher for Macintosh V1.2.0 program (Waydown South
Software, Dunedin, New Zealand) using FOODFiles, the New Zealand food composition database [14].
Missing food items were obtained from manufacturers’ information or other published references.
2.3. Insulin Sensitivity Measurements
Insulin sensitivity and other risk factors associated with the metabolic syndrome were assessed at
baseline, week 4 and week 10. Insulin sensitivity was assessed with the DISST method, conducted by a
research nurse, under medical supervision. After a 10–12 h fast, participants had a cannula inserted
into the antecubital fossa. Blood samples were drawn at t = 0, 10, 15, 25, and 35 min, for measurement
of plasma glucose, and serum insulin and C-peptide. A 10 g bolus of intravenous glucose was given at
t = 5 min, and 1 U of Actrapid insulin was given immediately after the t = 15-min sample.
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The DISST model estimates insulin sensitivity (SI), glucose distribution volume (Vg), and first-pass
(xL) and subsequent hepatic insulin clearance (nL) and three metrics of β-cell function, derived from
insulin production profiles and C-peptide data [11], following the methods of Van Cauter et al [15,16].
The basal rate (Ub) indicates the rate of insulin production that an individual requires to maintain
blood glucose at fasting levels. The area under the curve (AUC10) measures the first-phase insulin
production, produced immediately after the glucose bolus. AUC2nd measures the individual’s second
phase of insulin production during the 20 min after the period measured by AUC10 [11].
2.4. Laboratory Analyses
Whole blood samples were centrifuged at 1650 g for 15 min; then, samples were pipetted into
polyethylene cryovials and stored at −80 ◦C. Laboratory results, at all time-points, for all subjects,
were performed in batch, within the same assay. Serum insulin and C-peptide were measured using
a specific insulin electrochemiluminescence immunoassay (ECLIA) (Roche, Cat. No. 12017547) for
the Elecsys®analyzer (Roche Diagnostics, Mannheim, Germany), with a coefficient of variation of
1.5%. Serum total cholesterol (total-cholesterol and triglycerides (TG) concentrations were measured
enzymatically with Roche kits and calibrators on a Cobas Mira analyzer, as was plasma glucose
(Roche Hexokinase Cat. No. 11447513216). Coefficients of variation were 2.8% for total-cholesterol,
4.4% for TG and 0.5% for plasma glucose. HDL-cholesterol was measured in the supernatant
after precipitation of apolipoprotein B containing lipoproteins with phosphotungstate/magnesium
chloride solution [17] with a coefficient of variation of 3.6%. LDL-cholesterol was calculated using the
Friedewald equation: (total – cholesterol − HDL-cholesterol − (TG/2.18)) [18].
2.5. Analysis and Statistics
Insulin resistance was estimated by HOMA-IR index, using the HOMA-IR2 calculator [9] and by
the McAuley index, using fasting insulin and TG, where predicted insulin sensitivity is expressed as
an exponent (2.63 − 0.28 ln(fasting insulin) − 0.31 ln(fasting TG)) [10]. A McAuley index value ≤ 6.3
indicated insulin resistance.
The number of participants required to detect a 30% difference in insulin resistance, as assessed
by the HOMA-IR index, with 80% power, at a level of significance of 0.05, was 72. Statistical
analyses were performed using the STATA statistical software package 9.0 (Stata, College Station,
TX, USA). Baseline data are presented as mean (SD). Elsewhere, data are presented as mean (SE) or
as geometric means (min, max) for logarithmically transformed values. Data were analysed on a
modified intention-to-treat basis (i.e., without imputation of missing values), using a mixed model for
repeated measures, with “participant” as a random effect of the treatment over the two intervention
phases (weeks 0–4 and weeks 5–10) [19] and baseline values as a covariate [20] (overall model).
Interactions between time and diet were tested by including a term for “time × diet” in the model.
Since there were significant interactions between time and diet for some biochemical variables, the
effects of treatment at week 4 and week 10 were estimated separately by analysis of covariance, using
baseline values as a covariate. The overall model is also presented for variables where there was no
significant “time × diet” interaction. For dietary variables, only the overall model is shown. This does
not change the interpretation of the results, but has a conservative effect on statistical power since the
number of observations is decreased and the SE is increased with the separate analyses.
The estimates for all variables, except for those relating to body composition, have been further
adjusted for baseline weight and change in weight during the intervention period. This is because
the intention of the study was to assess the effect of macronutrient composition on insulin sensitivity,
independently of weight loss. Both unadjusted and adjusted models are presented.
A post-hoc analysis was conducted to examine the DISST insulin sensitivity and insulin secretion
models for interactions between insulin sensitivity status and diet group, by including an interaction
term for group × insulin resistance status. ISIclamp equivalent < 1.0 e−2 mg/kg/(pmol/L)/min was used
to define insulin resistance.
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3. Results
Table 1 presents the baseline characteristics of the participants who started the dietary intervention.
More participants were initially randomised to the HPHFib group (44 vs. 39), they were slightly older
and had a higher estimated prevalence of insulin resistance. There were 39 women in the HPHFib group
and 37 women in the standard diet group, for whom clinical and anthropometric data are reported.
Table 1. Baseline demographic and clinical details for all participants randomized to intervention.
Standard Diet Group HPHFib Group
n 39 44
Age (years) 1 39 (18–65) 44 (21–61)
Body Mass Index (BMI) (kg/m2) 2 32.3 (5.1) 32.9 (5.5)
Weight (kg) 2 89.1 (14.3) 87.8 (16.0)
Systolic blood pressure (mm Hg) 2 120 (14) 119 (14)
Diastolic blood pressure (mm Hg) 2 78 (8) 78 (8)
Glucose status
Normal 36 (92.3) 38 (86.4)
Impaired glucose tolerance 2 (5.1) 6 (13.6)
Diabetes 1 (2.6)
Menstrual Status
Premenopausal 22 (56.4) 26 (59.1)
Post-menopausal 16 (41.0) 12 (27.3)
Hysterectomy 1 (2.6) 6 (13.6)
Smoking history
Never smoked 24 (61.5) 31 (70.5)
Former smoker 15 (38.5) 11 (25.0)
Current smoker 0 2 (4.5)
On metformin 2 (5.1) 2 (4.5)
On lipid lowering medications 3 (7.7) 3 (6.8)
On blood pressure medications 4 (10.3 4 (9.1)
Insulin resistance 3 13 (33.3) 23 (52.3)
DISST Insulin resistance 4 31% 28%
1 mean (range); 2 mean (SD); all other values are n (%); 3 defined by the McAuley method where
Gffm/I ≤ 6.3 G/mU/l; 4 ISIclamp equivalent < 1.0 e−2mg/kg/(pmol/L)/min—Only calculated for participants for
whom Dynamic Insulin Sensitivity and Secretion Test (DISST) data was also available at week 4 or week 10 (n = 35
for StdD and n = 39 for the relatively high protein, high fibre diet (HPHFib)).
Baseline dietary macronutrient intakes were well matched (Table 2). Participants on the HPHFib
diet consumed significantly more protein and dietary fibre and less total fat and saturated fat than
the StdD group during the study, but there was no difference in total carbohydrate intake. Of the
increase in total dietary fibre, 38% was soluble fibre. On average, HPHFib participants consumed
10.1 (SE 13.5) g/day of whey protein powder providing 7.6 g/day protein. Legumes, lean mean and
chicken and fish provided the additional protein consumed by the HPHFib group. Reported energy
intakes declined over the 10 weeks in both the control and HPHFib groups but there was no evidence
of a difference between the two groups.
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StdD 8660 (2447) 7252 (1723) 7418 (1845) 0.0081
HPHFib 8332 (2414) 7549 (1473) 7155 (1218) 0.0064 193 (−408, 794) 0.386
Protein (% TE)
StdD 18 (3) 21 (6) 19 (4) 0.6986
HPHFib 18 (4) 25 (4) 24 (5) <0.0001 5.0 (3.2, 6.8) < 0.0001
Fat (% TE)
StdD 32 (7) 28 (5) 30 (6) 0.4272
HPHFib 31 (6) 25 (6) 25 (5) 0.0002 −4.5 (−6.8, −2.3) <0.0001
Saturated fat (% TE)
StdD 13 (4) 11 (3) 11 (3) 0.033
HPHFib 12 (3) 8 (3) 8 (3) <0.0001 −3.1 (−4.2, −2.0) <0.0001
Available carbohydrate (% TE)
StdD 45 (8) 47 (8) 46 (6) 0.8512
HPHFib 46 (6) 45 (5) 45 (5) 0.8963 −1.7 (−4.3, 1.0) 0.211
Dietary fibre (g/day)
StdD 24 (7) 24 (8) 22 (7) 0.2023
HPHFib 24 (6) 33 (9) 30 (7) 0.0004 9.6 (6.0, 13.1) <0.0001
Soluble fibre (g/day)
StdD 11 (3) 10 (3) 10 (4) 0.2454
HPHFib 11 (4) 14 (4) 13 (3) 0.0874 3.6 (2.0, 5.1) <0.0001
Insoluble fibre (g/day)
StdD 13 (4) 13 (5) 12 (5) 0.2838
HPHFib 12 (3) 18 (5) 16 (4) 0.0006 5.0 (2.9, 7.0) 0.0001
1 p-value for difference between week 0 and week 10. 2 As the time x group interaction effect was not
significant, a cross-sectional time-series regression model (xtreg) was used to obtain the estimate from week 4 and
week 10 measures. % TE = percentage of total daily energy intake.
Although the first 4 weeks of the study were intended to achieve weight maintenance, at week 4,
the HPHFib participants had lost a small amount of weight, whereas the StdD participants had not
changed. The difference between the groups was statistically significant. There was no further weight
loss in the second phase of the study. Body composition was only measured at baseline and week 10.
Total fat mass and truncal fat mass were lower in HPHFib than in StdD. Lean mass did not change in
either group and there was no difference in waist circumference (Table 3).
Table 3. Mean (SD) measures of body composition at baseline, week 4 1 and week 10 and adjusted
differences between dietary groups.




Baseline 89.2 (14.7) 85.4 (14.8)
Week 4 89.0 (15.2) 84.2 (14.5) −1.3 (−1.8, −0.7) <0.0001
Week 10 89.0 (15.1) 83.9 (14.5) −1.1 (−1.9, −0.3) 0.006
Fat mass (kg)
Baseline 40.9 (11.2) 39.1 (11.2)
Week 10 41.2 (11.5) 38.1 (10.8) −1.0 (−1.8, −0.2) 0.014
Fat mass (%)
Baseline 45.8 (6.3) 45.6 (6.0)
Week 10 46.2 (6.3) 45.0 (6.1) −0.6 (−1.30, 0.02) 0.059
Truncal fat mass (kg)
Baseline 21 (6.7) 19.9 (6.0)
Week 10 21.3 (6.9) 19.3 (5.8) −0.7 (−1.3, −0.1) 0.034
Lean mass (kg)
Baseline 44.3 (5.2) 42.5 (4.8)
Week 10 43.9 (5.1) 42.4 (4.7) 0.1 (−0.5, 0.6) 0.843
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Table 3. Cont.




Baseline 96.6 (11.5) 94.5 (13.3)
Week 4 95.6 (11.3) 93.2 (13.1) −0.8 (−2.3, 0.6) 0.266
Week 10 95.8 (12.0) 92.3 (12.6) −1.3 (−2.8, 0.2) 0.084
1 Dual x-ray absorptiometry (DXA) measures (fat and lean mass) were assessed at baseline and week 10 only;
2 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the
two intervention phases (weeks 0–4 and weeks 5–10), using baseline values as a covariate. As the time x group
interaction effect was not significant, a cross-sectional time-series regression model (xtreg) was used to obtain the
overall estimate from week 4 and week 10 measures.
In the unadjusted models, DISST insulin sensitivity was reduced in the HPHFib group, relative to
the StdD group, at both week 4 and week 10, but the difference between diets did not reach statistical
significance (i.e., p < 0.05) (Table 4). When DISST insulin sensitivity was adjusted for weight loss, there
was trend towards decreased insulin sensitivity at week 4 in the HPHFib group and a statistically
significant decrease in insulin sensitivity at week 10. There was a statistically significant reduction in
basal insulin secretion (Ub) in the HPHFib group compared with the StdD group at week 10, although
this was attenuated after adjustment for weight loss. In contrast, fasting glucose was significantly lower
at week 10 on the HPHFib diet in the unadjusted model but this effect was attenuated in the model
adjusted for weight loss. There was no evidence of differences in insulin concentrations, HOMA-IR2,
the McAuley insulin sensitivity index and SBP between treatments (Table 5).
Post-hoc analyses testing for interaction effects between diet group, insulin sensitivity status
and DISST metrics showed no significant differences between insulin sensitive and insulin resistant
individuals (range of p-values: 0.084 to 0.723). This indicates that insulin sensitivity decreased in both
insulin sensitive and insulin resistant individuals in the HPHFib group compared with those in the
StdD group.
There was also generally an improvement in lipid concentrations in the HPHFib group, whereas
there was no change in the control group. Total cholesterol was lower at both week 4 and week 10,
even after adjustment for weight loss and this was significantly different to the StdD group in whom
total-cholesterol increased. LDL cholesterol was also reduced in the HPHFib group and the difference
was significant at week 10 in the unadjusted model, although the effect was attenuated in the adjusted
model. On the other hand, there was a small reduction in HDL cholesterol at week 4 in the HPHFib
group but this had improved by week 10. TG was reduced in the HPHFib group and unchanged in the
StdD group, but the difference was not significant (Table 6).
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Table 4. Geometric mean (min, max) DISST measures of insulin sensitivity and secretion at baseline, week 4 and week 10 and percentage differences between dietary
groups adjusted for baseline values and weight change.
Std Diet HPHFib Difference between GroupsAdjusted for Baseline Value 1 p-Value
Difference between Groups Adjusted for




Baseline 0.95 (0.33, 2.63) 0.97 (0.39, 2.61)
Week 4 1.02 (0.38, 2.43) 0.91 (0.19, 2.47) −9.7% (−24.2%, 7.4%) 0.245 −13.6% (−29.5%, 6.1%) 0.16
Week 10 0.98 (0.35, 3.14) 0.86 (0.25, 1.8) −13.4% (−26.4%, 2%) 0.084 −19.3% (−31.8%, −4.5%) 0.013
Overall1 −12.1% (−23.5%, 1%) 0.069 −17.8% (−28.6%, −5.3%) 0.007
Basal insulin secretion, Ub, (pmol/min)
Baseline 215 (95, 380) 229 (94, 512)
Week 4 205 (99, 384) 229 (109, 429) 1.3% (−6%, 9.3%) 0.727 6.4% (−2.4%, 16%) 0.154
Week 10 218 (91, 444) 206 (88, 462) −12.1% (−20.4%, −2.9%) 0.012 −9.2% (−18.3%, 1%) 0.074
Overall Significant time × diet effect
1st phase AUC insulin secretion, AUC5−15, (pmol)
Baseline 4913 (1164, 16037) 5788 (2193, 13638)
Week 4 4619 (1195, 14788) 6028 (1686, 15186) 11% (−2.1%, 25.8%) 0.101 9.4% (−5.5%, 26.7%) 0.223
Week 10 4793 (1503, 13921) 5899 (2485, 16160) 6.9% (−3.8%, 18.8%) 0.209 7.2% (−4.1%, 19.9%) 0.216
Overall 9.2% (−0.5%, 19.9%) 0.064 9.2% (−1.2%, 20.7%) 0.084
2nd phase AUC insulin secretion, U2nd, (pmol)
Baseline 6143 (1588, 12350) 6388 (2750, 15932)
Week 4 5919 (1850, 12631) 6470 (2269, 17434) 1.9% (−8.3%, 13.3%) 0.719 5% (−7.2%, 18.9%) 0.433
Week 10 6088 (1933, 13892) 5969 (2238, 19210) −6% (−16.5%, 5.7%) 0.297 −6.6% (−17.9%, 6.2%) 0.29
Overall −2% (−11.2%, 8.1%) 0.688 −1.8% (−11.9%, 9.3%) 0.734
Total insulin secretion, Utotal, (pmol/L)
Baseline 15266 (7175, 27275) 16456 (6793, 37618)
Week 4 14538 (7156, 25774) 16927 (8061, 39962) 5.4% (−1.6%, 12.9%) 0.133 7.1% (−1.2%, 16.2%) 0.096
Week 10 15102 (7234, 27159) 15835 (6231, 43324) −3% (−10%, 4.4%) 0.411 −2.9% (−10.4%, 5.3%) 0.473
Overall Significant time*diet effect
1 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the two intervention phases (weeks 0–4 and weeks 5–10), using baseline
values as a covariate. If the time x group interaction effect was not significant, a cross-sectional time-series regression model (xtreg) was used to obtain the overall estimate from week 4
and week 10 measures. AUC: area under the curve.
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Table 5. Geometric mean (min, max) measures of insulin sensitivity, based on fasting blood samples at baseline, week 4 and week 10 and percentage differences
between dietary groups, adjusted for baseline values and weight change.
Standard Diet HPHFib Difference Adjustedfor Baseline Value 1 p-Value
Difference Adjusted for Baseline
Value and Weight Change 1
p-Value for
Overall Effect
Fasting plasma glucose (mmol/L)
Baseline 4.7 (3.8, 8.1) 4.7 (4.1, 5.7)
Week 4 4.7 (3.6, 6.4) 4.6 (3.8, 5.9) −0.5% (−3.3%, 2.4%) 0.74 1.2% (−2%, 4.5%) 0.449
Week 10 4.8 (3.9, 6.1) 4.6 (3.8, 5.8) −3.8% (−6.7%, −0.8%) 0.014 −3.1% (−6.3%, 0.1%) 0.057
Fasting plasma insulin (pmol/L)
Baseline 61.2 (18.8, 174.3) 77.5 (11.8, 729.9)
Week 4 57.0 (13.2, 206.3) 66.1 (13.9, 190.3) −4.1% (−20.2%, 15.2%) 0.649 4.7% (−15.1%, 29.1%) 0.664
Week 10 59.8 (20.8, 197.9) 63.4 (9, 206.3) −10% (−26.6%, 10.2%) 0.302 −2.1% (-21%, 21.3%) 0.844
McAuley IS index
Baseline 7.26 (3.3, 10.26) 6.69 (3.38, 14.23)
Week 4 7.45 (3.6, 13.95) 7.15 (4.61, 11.89) 4.2% (−3.6%, 12.6%) 0.295 0.4% (−8.1%, 9.6%) 0.932
Week 10 7.20 (3.55, 12.81) 7.30 (3.85, 15.26) 8.5% (−0.1%, 17.9%) 0.053 5.3% (−3.6%, 15%) 0.245
HOMA−IR Index
Baseline 1.28 (0.39, 3.69) 1.60 (0.24, 12.35)
Week 4 1.19 (0.28, 4.18) 1.37 (0.29, 3.79) −4.4% (−20.2%, 14.5%) 0.621 4.4% (−15.1%, 28.3%) 0.68
Week 10 1.26 (0.44, 4.08) 1.31 (0.18, 3.98) −11.2% (−27.3%, 8.4%) 0.24 −3.8% (−22.1%, 18.8%) 0.714
1 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the two intervention phases (weeks 0–4 and weeks 5–10) using baseline values
as a covariate. As the time × group interaction effect was not significant, a cross-sectional time-series regression model (xtreg) was used to obtain the overall estimates from week 4 and
week 10 measures; IS: Insulin sensitivity; IR: Insulin resistance.
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Table 6. Mean (SD) measures for other metabolic variables based on fasting blood samples and clinical measures at baseline, week 4 and week 10 and percentage
differences between dietary groups, adjusted for baseline values and weight change.
Standard Diet HPHFib Difference Adjustedfor Baseline Value 1 p-Value
Difference Adjusted for Baseline
Value and Weight Change 1 p-Value
Total cholesterol (mmol/L)
Baseline 4.87 (1.45) 4.57 (0.82)
Week 4 4.92 (1.58) 4.32 (0.82) −0.28 (−0.51, −0.04) 0.021 −0.25 (−0.48, −0.02) 0.031
Week 10 5.03 (1.62) 4.36 (0.79) −0.40 (−0.66, −0.15) 0.002 −0.36 (−0.63, −0.09) 0.01
LDL cholesterol (mmol/L)
Baseline 2.94 (1.00) 2.8 (0.74)
Week 4 2.92 (0.89) 2.69 (0.77) −0.11 (−0.3, 0.09) 0.274 −0.15 (−0.37, 0.07) 0.173
Week 10 3.00 (0.98) 2.66 (0.71) −0.25 (−0.48, −0.03) 0.029 −0.23 (−0.47, 0.01) 0.065
HDL cholesterol (mmol/L)
Baseline 1.13 (0.29) 1.19 (0.34)
Week 4 1.10 (0.28) 1.09 (0.28) −0.07 (−0.13, −0.02) 0.008 −0.07 (−0.13, −0.01) 0.032
Week 10 1.12 (0.29) 1.17 (0.34) −0.02 (−0.09, 0.05) 0.534 −0.02 (−0.1, 0.05) 0.486
Triglycerides (mmol/L)
Baseline 1.42 (1.45) 1.32 (0.60)
Week 4 1.37 (0.95) 1.21 (0.51) −0.09 (−0.28, 0.1) 0.351 −0.1 (−0.3, 0.09) 0.295
Week 10 1.42 (1.03) 1.21 (0.68) −0.14 (−0.38, 0.11) 0.272 −0.09 (−0.35, 0.17) 0.506
Systolic BP (mmHg)
Baseline 120.7 (14.2) 118.7 (15.0)
Week 4 124.1 (13.9) 117.0 (15.9) −3.8 (−11.0, 3.5) 0.299 −5.1 (−13.4, 3.1) 0.217
Week 10 121.9 (15.0) 117.1 (12.8) −2.0 (−7.4, 3.4) 0.469 −1.5 (−7.2, 4.3) 0.607
Diastolic BP (mmHg)
Baseline 77.8 (8.3) 78.2 (8.1)
Week 4 76.1 (8.1) 75.2 (10.2) −0.78 (−5.3, 3.7) 0.972 −1.1 (−6.0, 3.8) 0.641
Week 10 75.7 (8.1) 74.8 (8.0) −0.27 (−3.6, 3.1) 0.875 −0.1 (−3.6, 3.5) 0.972
1 A mixed model using “participant” as a random effect was used to estimate the effect of the treatment over the two intervention phases (weeks 0–4 and weeks 5–10), using baseline
values as a covariate. As the time × group interaction effect was not significant, a cross-sectional time-series regression model (xtreg) was used to obtain the overall estimates from week 4
and week 10 measures; BP: Blood pressure.
Nutrients 2017, 9, 1291 11 of 17
4. Discussion
This study showed that a modest increase in consumption of both dietary protein and fibre,
without emphasis on energy reduction, improved several cardiometabolic risk factors in overweight
women. There were modest reductions in body mass (1.2 kg), total body fat (1.0 kg) and central
body fat (0.7 kg), with no loss of lean mass and improvements in total serum and LDL cholesterol
concentrations. However, insulin sensitivity, as measured by DISST, declined throughout the 10-week
study, even during the first 4 weeks, when moderate weight loss was achieved.
Prospective analyses and lifestyle intervention studies indicate, with remarkable consistency, that
high fibre diets are associated with a reduced risk of diabetes and CVD. Cross-sectional analyses of
epidemiological studies, using static measures of insulin sensitivity, based on fasting concentrations of
glucose and insulin, such as the HOMA-IR index, show a positive association between dietary fibre [21–23]
or wholegrains [24,25] and insulin sensitivity. These findings are confirmed by cross sectional analyses,
using dynamic insulin and glucose stimulated models of insulin sensitivity, including the frequently
sampled intravenous glucose tolerance test [24] and the clamp [25]. Lifestyle intervention studies
also provide evidence for a beneficial effect of dietary fibre from wholegrains, fruit and vegetables on
insulin sensitivity [26,27] and reducing the risk of progression from impaired glucose tolerance (IGT)
to diabetes [28–30]. However, the effect of dietary fibre cannot be disentangled from the effect of other
changes made in conjunction with lifestyle improvement.
Various mechanisms have been proposed as to how dietary fibre might influence insulin sensitivity,
but there is as yet no definitive explanation. Refined carbohydrate foods are quickly absorbed and
have hyperinsulinaemic and hyperglycaemic effects—both of which can lead to the down-regulation
of GLUT 4 glucose transporters in peripheral tissues and a reduction in insulin sensitivity [31,32].
In contrast, intact or minimally processed high fibre carbohydrate foods and those with a low glycaemic
index (GI) are typically more slowly digested and absorbed, resulting in reduced glycaemic and
insulinaemic responses [33]. In addition, the fermentation of indigestible dietary fibre in the colon
produces short-chain fatty acids, which may also regulate glucose homeostasis by inhibiting hepatic
glucose production, stimulating hepatic glucose storage through glycogen synthesis and improving
peripheral insulin sensitivity [34].
A relatively small number of clinical trials, involving healthy, overweight, insulin resistant and
diabetic patients, have shown that wholegrain-rich, high fibre diets can improve insulin sensitivity
and glucose metabolism using direct methods of assessing insulin sensitivity relative to diets with
low-fibre diets or those based on refined grains [35–38], but the evidence is inconsistent [39].
Acute studies, comparing the effect of high fibre breads with lower fibre breads, are equally
conflicting [40,41]. However, there is no evidence to suggest that high fibre diets impair insulin
sensitivity. Studies examining the effect of GI on glucose homeostasis and direct measurements of
insulin sensitivity have also not shown conclusive benefits of low GI diets compared with high GI
diets. A carefully designed crossover study by Järvi and colleagues compared two identical diets
differing only in GI in subjects with type 2 diabetes mellitus (T2DM) [42]. Insulin sensitivity, measured
by the clamp, increased during both phases, but there was no effect of GI. However, day-long glucose
and insulin responses and lipid profile were significantly reduced on the low GI diet compared
with the high GI diet. Another study, which altered the GI and dietary fibre content of bread in
premenopausal women with IGT and a history of gestational diabetes, showed no effect of GI on
insulin sensitivity, although there appeared to be an improvement in glucose metabolism with the low
GI diet [43]. In contrast, Kiens and Richter reported reduced insulin sensitivity (measured with the
clamp) in healthy, lean men following a low GI, higher fibre diet compared with an isoenergetic high
GI diet [44]. Though limited and based on heterogeneous groups of subjects, this evidence is contrary
to the mechanistic evidence which has suggested that low GI diets might improve insulin sensitivity.
In fact, low GI diets appear to reduce insulin sensitivity when measured with direct methods, such as
the clamp, even though other aspects of glucose metabolism appear to be enhanced. This evidence is
compatible with the findings of our study.
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Few appropriately designed studies have investigated the effect of high protein (HP) diets on
insulin sensitivity using direct methods of assessment. Dietary interventions comparing HP and
high carbohydrate (HC) diets, designed to achieve weight loss of approximately 5% or more of total
body weight, suggest that HP diets may improve glucose metabolism and insulin sensitivity in obese
subjects [45,46] and those with T2DM [47,48]. However, in studies not involving weight loss, increased
dietary protein intake has been associated with a reduction in insulin sensitivity and alterations in
glucose metabolism that appear to be unfavourable [49,50]. An observational study showed that
adults who habitually consume high protein diets (>0.8g protein/kg/day) have reduced insulin
sensitivity, lower rates of glucose oxidation, greater endogenous glucose production and greater
net gluconeogenesis than those consuming low protein diets (<0.8 g/kg/day) [51]. A follow-up
randomised trial, comparing weight maintaining diets in overweight adults, found reduced insulin
sensitivity (measured by the clamp) in those following a HP diet compared with those on a HC diet
that was high in cereal fibre, after 6 weeks. However these differences were attenuated after 18 weeks,
possibly as a result of decreased adherence to the HP diet [52] or effects of changes in amino acid
metabolism [50]. In contrast, two recent studies comparing HP diets with either a standard protein diet
matched for carbohydrate intake [53] or a HC diet [54] found no differences in insulin sensitivity after
four to six weeks under weight maintenance conditions. This suggests that carbohydrate quality may be
more influential with regard to insulin sensitivity than the quantity of dietary protein or carbohydrate.
Nevertheless, there is mechanistic evidence which gives weight to the suggestion that excessive protein
consumption could lead to impaired insulin sensitivity and glucose metabolism [49,55]. In humans
an increase in plasma amino acid concentrations (by intravenous infusion) has been shown to cause
a reduction in insulin-stimulated peripheral glucose uptake by inhibiting glucose transport [55,56],
while cell-culture studies have also demonstrated that excess amino acids inhibit glucose transport
and suppress insulin-mediated inhibition of hepatic gluconeogenesis [57]. These effects appear to
be related to activation of the Mammalian Target of Rapamycin (mTOR) nutrient sensing pathway
which mediates protein synthesis [58]. mTOR activates the p70 S6 kinase 1 (S6K1) pathway, which
phosphorylates and inhibits the insulin receptor substrate (IRS1), resulting in an apparent reduction in
insulin sensitivity. Weickert and colleagues showed that S6KI expression was increased in subjects
consuming a high protein diet over 6-weeks in association with a reduction in insulin sensitivity [52].
Layman and Baum [59] propose an alternative theory: dietary protein stabilizes blood glucose
concentrations when protein intakes are high. Dietary protein is more slowly metabolized than dietary
carbohydrate, resulting in lower postprandial glucose and insulin responses after a high protein meal
compared with a high carbohydrate meal [60,61]. Therefore while a HC diet necessitates rapid insulin
responses and corresponding rapid peripheral uptake of glucose to maintain acceptable blood glucose
concentrations, it follows that a HP, reduced carbohydrate diet may require a modulation of peripheral
glucose uptake to maintain glucose homeostasis and prevent hypoglycaemia [59]. The brain uses
glucose almost exclusively as a fuel source and a constant supply of blood glucose is critical to sustain
brain activity [62]. However high concentrations of glucose are toxic and thus glucose must be tightly
regulated [62]. Muscle is the principal site of insulin-stimulated glucose disposal in the body and
glucose transport into skeletal muscle is the rate-controlling step in glucose metabolism [32]. The rate
of glucose transport is likely to be determined by the expression and activity of proteins involved in the
signalling pathways regulating the translocation of GLUT-4 from intracellular vesicles to the plasma
membrane [32]. In individuals with insulin resistance, the regulation of GLUT-4 may be inappropriate
in response to abnormal circulating levels of a wide range of factors, including excess free fatty acids,
glucose and cytokines [32]. Glucose transport may also be regulated by metabolites that act as cellular
fuel sensors such as AMPK—a protein kinase, which is regulated by changes in the cellular ratio of
AMP to ATP [63]. An observational study by Harber and colleagues provided interesting evidence of
the capacity of the metabolic system to adapt to changes in the nature of the fuel supply [64]. In this
study, subjects were fed a very low carbohydrate diet (5% carbohydrate, 65% fat, 30% protein) for
seven days. Such severe dietary carbohydrate restriction required marked metabolic adaptions to
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prevent hypoglycaemia. After 2 days, post-absorptive glucose concentrations were reduced from
baseline. However, from day 3 until the end of the study glucose returned to normal levels, suggesting
an adaptation to the to the diet had occurred in order to maintain glucose homeostasis. Using isotope
dilution methods, the researchers determined that peripheral glucose uptake was decreased for the
duration of the study, while glucose oxidation was reduced by 43% and the rate of non-oxidative
glucose uptake (i.e., for storage as glycogen) was increased. A decrease in 24-h insulin concentrations
was observed, which may have contributed to increased hepatic glucose production, by stimulating
gluconeogenesis and lipolysis.
Participants on the HPHFib diet in our study increased their absolute protein intakes as well as
intakes of minimally processed, high fibre carbohydrates. Although we did not measure postprandial
glucose responses, the meals consumed by those on the HPHFib would have been more slowly
absorbed than StdD meals thus leading to a more stable glycaemic environment and less reliance on
rapid postprandial insulin-stimulated, peripheral glucose disposal during the 10-week intervention.
Therefore, on the HPHFib diet, it is conceivable that glucose transport was down-regulated to prevent
hypoglycaemia [65]. Based on our observations we propose that after the intravenous glucose
administration during the DISST, glucose uptake in peripheral tissues in the HPHFib group could not
occur as rapidly as in the StdD group, due to a diet-induced adaptation to a slower rate of glucose
arrival in the blood. In conjunction with a decrease in the rate of glucose uptake, there would be
a temporary rise in plasma glucose concentrations, resulting in an increase in first phase insulin
secretion (AUC5–15).
The fact that the HPHFib and StdD groups did not receive similar attention might be perceived to
be a weakness of the main study [12]. However, the purpose of this analysis was to demonstrate how
the achieved dietary changes influenced insulin sensitivity, as assessed by the DISST approach [11],
rather than to argue for the benefits of a HPHFib diet.
The use of the novel DISST method to directly assess insulin sensitivity and secretion is a strength
of this study. The DISST method correlates extremely well with the gold standard euglycaemic clamp
and will generate diagnostic insulin sensitivity values with much greater sensitivity and specificity
than values generated by crude index indices based on fasting blood parameters, such as HOMA-IR [9]
and the McAuley method [10]. Although DISST has not previously been used to assess the effects of
dietary change, we believe it may be a superior test to the clamp, measuring insulin sensitivity in a
more physiologically representative state and providing information on insulin secretion dynamics.
5. Conclusions
Insulin sensitivity, measured by the novel DISST method, was reduced in overweight women
at risk of diabetes following an ad libitum high protein, high fibre diet, compared with those
following a standard ad libitum high carbohydrate, low fat diet, after accounting for weight loss
differences. However, there was a corresponding improvement in body composition and conventional
cardiometabolic risk factors, including static indices of insulin sensitivity. Therefore, we propose that
dynamic insulin sensitivity indicators may reflect metabolic adaptations to usual dietary intakes for
maintenance of glucose homeostasis rather than an increase in risk of diabetes, and question their
validity in dietary intervention studies. Further studies are required to explain and verify these effects.
The cardiometabolic benefits achieved with moderate increases to fibre and protein, without emphasis
on energy reduction support the use of this approach for overweight individuals at risk of diabetes.
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